Drug intelligence / Profile preview

sacriolimab

Development stage: Unknown
Lead developer: Merck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Sacriolimab is an anti-CD24 monoclonal antibody that was originally developed by OncoImmune. It was acquired by Merck as part of a strategy to expand Merck's immuno-oncology pipeline. The drug was in Phase 3 clinical trials for the treatment of COVID-19. Its mechanism of action involves targeting CD24, a cell surface protein.

Targets

CD24 (Cluster of Differentiation 24)

Beyond the preview

Go deeper on sacriolimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sacriolimab.

Explore the full profile